exo-Tetrahydrocannabivarin (Compound 12) is a Δ9,11-THC analogue. exo-Tetrahydrocannabivarin weakly binds to cannabinoid receptors (CB) (IC50: 1.4 μM). exo-Tetrahydrocannabivarin is active on both motor and analgesic aspects in mice.

Dehydrocannabifuran (6-Methyl-9-isopropenyl-3-pentyldibenzofuran-1-ol) is a phytocannabinoid derivative.

CHM-FUBIATA is structurally similar to known synthetic cannabinoids.

CH-FUBIATA is structurally similar to known synthetic cannabinoids.

CE-178253 benzenesulfonate is a CB1 antagonist with central nervous system activity.

Carmagerol is a phytocannabinoid metabolite.

Cannabiorcol (Cannabinol C1) is structurally similar to known phytocannabinoids.

Cannabinol methyl ether is a phytocannabinoid.

Cannabinol ethyl (CBN-C2) is structurally similar to known phytocannabinoids.

Cannabinol acetate (Acetylcannabinol) is structurally similar to known phytocannabinoids.

Cannabigerorcinic acid is structurally similar to known phytocannabinoids.

Cannabigerorcin is a phenolic compound found in cannabis plants, featuring a diphenol backbone and a terpene side chain. By reacting with radiolabeled methylmagnesium carbonate (MMC), its carboxyl group can be 14C-labeled. Radiolabeled Cannabigerorcin is widely used in research on cannabinoid biosynthesis pathways and metabolic processes.

Cannabigerophorol (CBGP) is structurally similar to known synthetic cannabinoids.

Cannabigerolic acid monomethyl ether is structurally similar to known phytocannabinoids.

Cannabigerol diacetate is structurally similar to known phytocannabinoids.

Cannabigerobutolic acid (CBGBA) is structurally similar to known phytocannabinoids.

Cannabidivarin diacetateis structurally similar to known phytocannabinoids.

Cannabidiol-C8 is structurally similar to known phytocannabinoids.

Cannabidiol monomethyl ether is a phytocannabinoid.

Cannabidihexol is a phytocannabinoid with analgesic activity in mice.

BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding.

BB-223-carboxyindole metabolite (B-223-Carboxyindolemetabolite) is a metabolite of BB-22. BB-22 is an analog of cannabinoid.

Azidoindolene 1 is structurally similar to cannabinoid.

APP-FUBINACA is a cannabinoid receptor agonist and a derivative of phenylalaninamide-based indazole-3-carboxamide. APP-FUBINACA exhibits neurostimulatory effects.

Afubiata is structurally similar to known synthetic cannabinoids.

ADB-BINACA is categorized as a synthetic cannabinoid.

ADB-BICA is structurally classified as a synthetic cannabinoid.

AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (Ki= 0.9 nM), exhibiting anticonvulsant activity.

AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms.

ABD459 is a CB1 receptor antagonist with significant effects on regulating food intake and sleep-wake cycles. ABD459 completely displaces CB1 agonist CP99540 (Ki = 8.6 nM) and antagonizes CP55940-induced GTPγS binding (KB = 7.7 nM). ABD459 may specifically modulate endogenous cannabinoid release through cholinergic activity and plays a role in attention and arousal regulation. ABD459 is suitable for research in neurological disorders.